Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
In individuals younger than age 50 undergoing a colonoscopy, greater odds for having colorectal cancer were observed among those who presented with rectal bleeding, according to findings from a study presented at the American College of Surgeons (ACS) Clinical Congress 2025 and published in the
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
In an Australian and New Zealand phase II trial (MOST-CIRCUIT) reported in JAMA Oncology, Carlino et al found that combined anti–PD-1/CTLA-4 blockade was associated with a high rate of durable responses in patients with advanced mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) ...
T-DXd Plus Pertuzumab in HER2-Positive Advanced or Metastatic Breast Cancer
As reported in The New England Journal of Medicine by Tolaney et al, interim analysis of the phase III DESTINY-Breast09 trial has shown significantly improved progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) plus pertuzumab vs a taxane (paclitaxel or docetaxel), trastuzumab,...
AACR Pediatric Cancer Progress Report Highlights Advances Made, Long-Term Survivorship Challenges, and Persistent Disparities in Care
Although treatment advances in pediatric cancers have resulted in increases in overall 5-year survival for children and adolescents diagnosed with cancer, many pediatric survivors face chronic health conditions as they age, as well as financial, social, and psychological challenges, according to...
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
As reported in The Lancet Oncology by Qin et al, the final analysis of the phase III CARES-310 trial has shown superior overall survival with camrelizumab plus rivoceranib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma.
Initial reports from the study...
FDA Approves CAR T-Cell Therapy for Relapsed/Refractory Marginal Zone Lymphoma
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior...
Total Neoadjuvant Therapy and Nonoperative Management in pMMR/MSS Stage II to III Rectal Cancer
In an Italian phase II trial (NO-CUT) reported in The Lancet Oncology, Amatu et al found that total neoadjuvant therapy followed by nonoperative management in cases of complete response resulted in promising outcomes in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS)...
Fuzuloparib in HER2-Negative Metastatic Breast Cancer With Germline BRCA1/2 Mutations
In an interim analysis of a Chinese phase III trial (FABULOUS) reported in The Lancet Oncology, Li et al found that the addition of the PARP inhibitor fuzuloparib to apatinib and fuzuloparib alone improved progression-free survival vs chemotherapy in patients with HER2-negative metastatic breast...
Renuka Iyer, MD, Named New Chief Medical Officer for NCCN
The National Comprehensive Cancer Network® (NCCN®) has announced the hiring of Renuka Iyer, MD, as the new Chief Medical Officer (CMO) for the organization.
Dr. Iyer has a long history of leadership and innovation in oncology. She currently serves as a Professor of Oncology for Roswell Park...
ASCO Statement on the Departure of Richard Pazdur, MD, From the FDA
Richard Pazdur, MD, Director of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA) and former long-time head of the FDA Oncology Center of Excellence (OCE), is leaving the FDA.
Dr. Pazdur has served the FDA for 26 years and is an expert in drug regulation. ...
Mammography-Based Outreach Increases Lung Cancer Screening Enrollment in Eligible Women
Women who undergo mammography to screen for breast cancer can be reviewed and recommended for additional lung cancer screening, thereby increasing enrollment, according to the results of a study published in the Journal of the American College of Radiology. The study, called Coordinate a Lung...
Pancreatic Cancer Detection: AI vs Radiologists
In a study (PANORAMA) reported in The Lancet Oncology, Alves et al found that an artificial intelligence (AI) program developed by the investigators was significantly better at detecting pancreatic ductal adenocarcinoma when applied to standard-of-care computed tomography (CT) scans than were...
Are Glycemic Index and Load Associated With Lung Cancer Risk?
Based on the results of a population-based cohort study published in Annals of Family Medicine by Wang et al, high dietary glycemic index is linked to increased risks of lung cancer, non–small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), whereas glycemic load is inversely associated ...
Upfront Reduced-Dose Enfortumab Vedotin With Pembrolizumab in First-Line Treatment of Advanced Urothelial Cancer
In a U.S. retrospective cohort study reported in JAMA Oncology, Chow et al found that reduced-dose vs standard upfront enfortumab vedotin-ejfv plus pembrolizumab reduced the risk of enfortumab vedotin treatment interruption in the first-line treatment of patients with advanced urothelial cancer.
...
Second-Line Pembrolizumab Plus Lenvatinib in Pleural Mesothelioma
In a cohort of a Dutch single-center phase II study (PEMMELA) reported in The Lancet Oncology, Douma et al found that pembrolizumab plus lenvatinib was active in patients with pleural mesothelioma whose disease progressed after treatment with nivolumab plus ipilimumab.
In cohort 1 in the trial,...
FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL
On December 3, the U.S. Food and Drug Administration (FDA) granted traditional approval to pirtobrutinib (Jaypirca), a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have...
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening: Current vs 100% Screening Uptake
In a study reported as a research letter in JAMA, Bandi et al compared estimated deaths prevented and life-years gained with current uptake vs 100% uptake of annual lung cancer screening in eligible U.S. individuals.
Study Details
The study used data obtained from the 2024 National Health...
AYA Cancers: Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Almost 10% of adolescents and young adults (AYAs) diagnosed with earlier-stage cancer develop metastatic disease, and survival outcomes were found to be worse for patients who developed metastatic recurrence compared with those who had metastatic disease at initial diagnosis for almost all analyzed ...
Survey Finds Global Embrace of Integrative Cancer Care
Around the world, doctors, nurses, and pharmacists are turning to evidence-based integrative approaches such as acupuncture, yoga, exercise, massage, and nutrition counseling to help people with cancer manage the harsh side effects of treatment, according to the results of a recent survey.
The new ...
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
In a single-center phase II trial (LUNAR) reported in the Journal of Clinical Oncology, Kishan et al found that the addition of neoadjuvant prostate-specific membrane antigen (PSMA)-targeting radioligand therapy with lutetium-177–labeled PNT2002 (LuPSMA PNT2002) to stereotactic body radiotherapy...
Preliminary Activity of LuPSMA-I&T Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis
In an interim analysis of an Australian single-center phase I/II trial (AlphaBet) reported in The Lancet Oncology, Kostos et al found that the combination of lutetium Lu-177–labeled PSMA–I&T (LuPSMA-I&T) and the bone-seeking alpha-emitter radium Ra-223 dichloride (Ra-223) was active in...
Image-Only AI Model Outperforms Breast Density Assessment for 5-Year Breast Cancer Risk Stratification
An image-only artificial intelligence (AI) model demonstrated stronger and more precise risk stratification than breast density assessment for predicting 5-year risk for developing breast cancer, according to findings from a study presented at the 2025 Annual Meeting of the Radiological Society of...
Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma: 5-Year Outcomes From the JULIET Trial
As reported in the Journal of Clinical Oncology by Maziarz et al, 5-year analysis of the pivotal phase II JULIET trial has shown maintained efficacy of tisagenlecleucel in patients with relapsed or refractory large B-cell lymphoma.
Study Details
In the trial, 115 patients received...
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
Up to 24% of breast cancers diagnosed in an 11-year period between seven outpatient facilities around New York were found in women aged 18 to 49 years, according to findings presented during the 2025 Annual Meeting of the Radiological Society of North America (RSNA; Abstract S5-SSBR02-1).
“This...
Is Chronic Hepatitis C Infection Associated With Pancreatic Cancer?
A retrospective, national, population-based cohort study of 6.3 million veterans, which was published in JAMA Network Open, found that individuals with chronic hepatitis C virus developed pancreatic ductal adenocarcinoma at younger ages and had a higher risk compared with those without the...
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced...
First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer: Outcomes Associated With Consensus Molecular Subtypes
In an individual patient meta-analysis reported in the Journal of Clinical Oncology, Stahler et al identified outcomes associated with consensus molecular subtypes (CMSs) in patients undergoing first-line treatment for RAS wild-type metastatic colorectal cancer.
Study Details
Individual patient...
Addition of Pirfenidone to Glucocorticoids in Grade 2 or 3 Radiation-Induced Lung Injury
In a Chinese phase II trial reported in The Lancet Oncology, Hou et al found that the addition of the antifibrotic pirfenidone to glucocorticoid treatment significantly improved the carbon dioxide diffusing capacity (DLCO%) in patients with grade 2 or 3 radiation-induced lung injury.
Study Details
...
Lung Cancer Screening Criteria: NELSON vs PLCOm2012
In a German study (HANSE) reported in The Lancet Oncology, Vogel-Claussen et al found that the PLCOm2012 low-dose computed tomography (CT) lung cancer screening eligibility criteria were more effective than the NELSON criteria in the detection of lung cancer.
Study Details
The prospective cohort...
ADCs vs Standard Chemotherapy: Cardiotoxicity in HER2-Positive Advanced Breast Cancer
A systematic review and meta-analysis published in JAMA Network Open compared the cardiotoxicity of novel antibody-drug conjugates (ADCs) with that of standard trastuzumab-containing chemotherapy in patients with HER2-positive locally advanced or metastatic breast cancer, finding that treatment...
FDA Approves Durvalumab With FLOT for Resectable Gastric/GEJ Adenocarcinoma
On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for the treatment of adult...
AI Simplifies Patients' Comprehension of CT Reports—but Errors Are Possible
Simplified oncologic computed tomography (CT) reports using large language models (LLMs) enabled patients to better understand the results of their restaging CT scans and reduced overall reading burden, according to the results of a study published in Radiology. However, the study also revealed...
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration...
FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle-Invasive Bladder Cancer
On November 21, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) or the subcutaneous formulation pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) in combination with enfortumab vedotin-ejfv (Padcev) as neoadjuvant treatment followed by adjuvant treatment...
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?
Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery...
Large AI Breast Cancer Screening Trial Increases Detection Rate by 20%
Using an artificial intelligence (AI)–integrated workflow, DeepHealth, in computer-aided detection of breast cancer from digital breast tomosynthesis exams found 21.6% more cases than the usual standard of care, according to findings from the AI-Supported Safeguard Review Evaluation (ASSURE) study...
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
In the final analysis of the phase III POTOMAC trial reported in The Lancet, De Santis et al found that the addition of durvalumab to bacillus Calmette-Guérin (BCG) induction and maintenance improved disease-free survival in patients with high-risk non–muscle-invasive bladder cancer (NMIBC) who...
ASTRO Experts Comment on the Results of the SUPREMO Trial
A large international study published by Kunkler et al in The New England Journal of Medicine examined whether chest wall radiation therapy after mastectomy improves survival for patients with early-stage breast cancer. The study, known as the SUPREMO trial, found no overall survival difference...
Cervical Cancer: SLNB Alone vs Lymphadenectomy
In a Chinese phase III trial (PHENIX) reported in The New England Journal of Medicine, Tu et al found that sentinel lymph node biopsy (SLNB) alone was noninferior in disease-free survival vs lymphadenectomy in women with early-stage cervical cancer and was associated with fewer surgical...
Traditional Approval Granted to Tarlatamab-dlle for Extensive-Stage SCLC
On November 19, the U.S. Food and Drug Administration (FDA) granted traditional approval to tarlatamab-dlle (Imdelltra), a DLL3-targeting bispecific T-cell engager, for adults with extensive-stage small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Melanoma Cancer Cluster Found in Parts of Pennsylvania
Researchers have identified a melanoma cancer cluster in 15 counties in Pennsylvania near or containing cultivated croplands, according to findings published in JCO Clinical Cancer Informatics. The research highlights that sunlight and areas of higher herbicide use may contribute to these...
FDA Grants Accelerated Approval to Sevabertinib for Nonsquamous NSCLC
On November 19, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adults with locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) whose tumors have HER2 tyrosine kinase domain (TKD) activating...
Patient Immune System Characteristics and Long-Term Remission From CAR T-Cell Therapy in Multiple Myeloma
Patients with relapsed or refractory multiple myeloma who achieve a long-lasting disease remission from chimeric antigen receptor (CAR) T-cell therapy may differ from patients who relapse sooner based upon their immune system and how it responds to the infused CAR T cells, as well as how it...
Vorasidenib in IDH1/2-Mutant Low-Grade Glioma
As reported in The Lancet Oncology by Cloughesy et al, vorasidenib was associated with improvement in some secondary and exploratory outcomes vs placebo in the phase III INDIGO trial in patients with residual or recurrent IDH1-mutant or IDH2-mutant low-grade glioma.
Initial reports at second...
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
Using a computational tool, DeepTarget, physicians were able to predict both primary and secondary targets of small-molecule agents for cancer treatment, according to findings from a study published in npj Precision Oncology. The study authors suggest that this represents a potentially significant...
Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer
As reported in the The New England Journal of Medicine by Kunkler et al, the phase III SUPREMO trial showed no significant difference in 10-year overall survival in women with breast cancer receiving vs not receiving postmastectomy chest-wall irradiation.
Study Details
In the international trial...
Newly Diagnosed AL Amyloidosis: FDA Grants Traditional Approval to Regimen
On November 19, the U.S. Food and Drug Administration (FDA) granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro) with bortezomib, cyclophosphamide, and dexamethasone (VCd) for newly diagnosed light chain (AL) amyloidosis. The FDA granted accelerated approval to the...
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
Curative treatment following first-line immunotherapy is infrequently received, but when it was utilized, it significantly improved overall survival outcomes for patients with hepatocellular carcinoma, according to findings from a study published in Liver Cancer. The risk for death was improved by...
FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas
On November 19, the U.S. Food and Drug Administration (FDA) approved selumetinib (Koselugo), a MEK inhibitor, for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). In September 2025, the FDA approved selumetinib capsules and granules for...
New Study Explores Why Male Patients With AML May Have Worse Outcomes
New research has ruled out hormone signaling as the reason why men with acute myeloid leukemia (AML) tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy—a finding that helps refine future research and could influence clinical trial design.
The...
Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation
A randomized controlled trial investigating the effect of providing personalized risk information to patients and their providers about the patient’s risk for advanced colorectal neoplasia has found no difference in screening uptake with either the personalized risk messages or provider...
Does Kidney Stone History Impact Survival Outcomes in Upper Tract Urothelial Carcinoma?
Based on the results of a multicenter retrospective cohort study published in JAMA Network Open, in patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma, a history of urinary stones was associated with significantly worse cancer-specific and disease-free survival....
Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer
In a Canadian phase III trial (MAST) reported in the Journal of Clinical Oncology, Fleshner et al found that metformin did not improve progression-free survival vs placebo in men with low-risk prostate cancer undergoing active surveillance.
Study Details
In the multicenter double-blind trial, 408 ...
Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma
In an interim analysis of a Chinese phase III trial (BL-B01D1-303) reported in The Lancet, Yang et al found that izalontamab brengitecan (iza-bren)—a bispecific antibody–drug conjugate targeting EGFR and HER3—significantly improved the objective response rate vs physician’s choice of chemotherapy...
FDA Approves Epcoritamab for Two Follicular Lymphoma Indications
On November 18, 2025, the U.S. Food and Drug Administration (FDA) approved epcoritamab-bysp (Epkinly), a bispecific CD20-directed CD3 T-cell engager, in combination with lenalidomide and rituximab for the treatment of patients with relapsed or refractory follicular lymphoma.
In addition, the FDA...
Dexrazoxane Use and Cardiovascular Health-Care Utilization in Children With Acute Myeloid Leukemia
In a U.S. cohort study reported as a research letter in JAMA Oncology, Zheng et al found that increasing use of dexrazoxane in newly diagnosed children with acute myeloid leukemia (AML) receiving front-line anthracycline treatment has been accompanied by a reduction in intensive care unit...
Quality Improvement Program Cuts Missed Radiation Appointments by 40%
A national quality improvement program led by the American College of Surgeons (ACS) found that transportation barriers and illness are among the top reasons patients with cancer miss critical radiation therapy appointments—and that providing hospitals and patients with structured support can...
Could a Liquid Biopsy Lead to Earlier Diagnoses for Numerous Cancer Types?
Routine screening is limited to only a few cancer types. New research indicates that routine liquid biopsy testing (multicancer early detection testing) could substantially reduce late-stage cancer diagnoses, allowing patients to receive treatment at earlier stages of disease, when they are more...
Does Regular Opioid Use Increase Risks for Certain Cancers?
Regular pharmaceutical opioid use was found to be associated with an elevated risk for cancers previously associated with opium consumption, but not for other cancers, according to findings from a large-scale study led by the International Agency for Research on Cancer (IARC) that was published in
More Patients With Cancer Are Using Crowdfunding to Pay for Care—and Coming up Short
Studies show that cancer is one of the leading diseases among all medical crowdfunding campaigns, with GoFundMe being the most popular platform for peer-to-peer medical donations. A new study by researchers at the American Cancer Society (ACS) has found that a growing number of cancer survivors are ...
FDA Approves Ziftomenib for NPM1-Positive AML
On November 13, 2025, the U.S. Food and Drug Administration (FDA) approved ziftomenib (Komzifti), a menin inhibitor, for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options...
Pancreatic Cancer: Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients
Mild dilation of the main pancreatic duct without an apparent obstructing mass may be an independent risk factor for neoplastic progression to pancreatic cancer in high-risk individuals, according to findings from an analysis published in Gastro Hep Advances.
“We are identifying pancreas duct...
SABR May Be Comparable to Surgery for Early-Stage NSCLC
Stereotactic radiation therapy (SABR) was found to be noninferior to surgical resection in terms of overall survival for patients with early-stage non–small cell lung cancer (NSCLC), according to 10-year results from the STARS trial presented at the American Society for Radiation Oncology (ASTRO)...
MD Anderson Launches $2.5 Billion Philanthropic Campaign: Only Possible Here, The Campaign to End Cancer
The University of Texas MD Anderson Cancer Center has launched its historic $2.5 billion comprehensive philanthropic campaign, Only Possible Here, The Campaign to End Cancer. The campaign represents the largest fundraising effort in MD Anderson's 84-year history, bringing together philanthropic...
Long-Term Continuous Nirogacestat in Adults With Desmoid Tumors
As reported in the Journal of Clinical Oncology by Ratan et al, long-term follow-up in the phase III DeFi trial has shown maintained benefits with prolonged nirogacestat treatment in patients with desmoid tumors.
Study Details
In the double-blind trial, 142 patients with progressing desmoid...
FDA Approves New Interchangeable Biosimilar to Pertuzumab
The U.S. Food and Drug Administration (FDA) has approved pertuzumab-dpzb (Poherdy) as an interchangeable biosimilar to pertuzumab (Perjeta). This is the first approval of a biosimilar for pertuzumab.
Pertuzumab-dpzb is a HER2/neu receptor antagonist indicated for the following:
- Use in...
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma
In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was associated with higher pathologic response rates vs perioperative FLOT (fluorouracil, leucovorin,...
Ezabenlimab, Induction Chemotherapy, and Adaptive Chemoradiotherapy in Stage III Squamous Cell Anal Carcinoma
In a French phase II trial reported in The Lancet Oncology, Kim et al found that the combination of the PD-1 inhibitor ezabenlimab and induction chemotherapy with modified docetaxel, cisplatin, and fluorouracil (mDCF) and adaptive chemoradiotherapy was active in patients with treatment-naive stage...
Transfusion Access Central to Hospice Decision-Making Among Patients With Blood Cancers
Based on the results of a multicenter cross-sectional survey study published in JAMA Network Open by Raman et al, patients with blood cancer who were potentially hospice-eligible placed the greatest importance on transfusion access compared with routine hospice services.
“The high value placed on...
Advanced Epithelial Ovarian Cancer: First-Line PARP Inhibitor Maintenance Therapy and Survival
A systematic review and meta-analysis published in JAMA Network Open found first-line PARP inhibitor maintenance after platinum-based chemotherapy was linked to improved progression-free survival across multiple patient populations with advanced-stage epithelial ovarian cancer. However, according...
Underlying Mechanisms of Chemoresistance in AML
Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer Discovery. They identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...
Exercise Training Improves Strength and Quality of Life for Patients With Metastatic Breast Cancer
Supervised aerobic and resistance exercise can improve the physical performance and strength of patients living with metastatic breast cancer, according to new data from the PREFERABLE-EFFECT study that was presented by Anne May, PhD, during the Advanced Breast Cancer Eighth International Consensus ...
Supportive Care: Most Clinic Staff Prefer People-Focused vs Digital Solutions
Most cancer clinic staff prefer a team-based approach to supportive cancer care services over a technology-based approach, according to the results of a mixed-methods study of supportive care perceptions that was published in JNCCN—Journal of the National Comprehensive Cancer Network. The study...
Addition of Eryaspase to Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
In a phase III trial (TRYBECA-1) reported in the Journal of Clinical Oncology, Hammel et al found that the addition of eryaspase (suspension of erythrocytes encapsulating L-asparaginase) to chemotherapy did not significantly improve outcomes in second-line treatment of patients with advanced...
Longtime FDA Innovator Appointed as Director of CDER
The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) announced that Richard Pazdur, MD, has been appointed Director of the Center for Drug Evaluation and Research (CDER). Dr. Pazdur is a 26-year veteran of the FDA and the Founding Director of its...
Local Consolidative Therapy Enhances Outcomes With Osimertinib in EGFR-Mutant NSCLC
Osimertinib in combination with local consolidative therapy of radiation and/or surgery led to a significant extension of progression-free survival for patients with EGFR-mutant metastatic non–small cell lung cancer (NSCLC), according to findings from the phase II NorthStar trial presented at the...
Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib/Chemotherapy in EGFR-Positive NSCLC
The combination of osimertinib plus chemotherapy led to a median overall survival of 47.5 months compared with 37.6 months with osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who had not received prior treatment for advanced disease, according to...
Routine AI Assistance May Lead to Loss of Skills in Endoscopists, Study Shows
The introduction of artificial intelligence (AI) to assist colonoscopies may be linked to a reduction in the ability of endoscopists to detect adenomas in the colon without AI assistance, according to a paper published by Budzyń et al in The Lancet Gastroenterology & Hepatology.
Colonoscopy...
HER3-DXd in Patients With Active Brain Metastases From NSCLC and Breast Cancer
In the phase II TUXEDO-3 trial—reported in two articles in The Lancet Oncology—Fuereder et al and Bartsch et al found that the topoisomerase-1 HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was active in cohorts of patients with active brain metastases from advanced...
Survey Highlights Unmet Needs Among Young Women With Advanced Breast Cancer
Almost half of all women (48%) under the age of 40 who are living with advanced breast cancer have children under the age of 18, and 64% of these young patients also experience employment disruptions after they are diagnosed, according to findings from a survey conducted by the Young Survival...
Global Report Highlights Decade of Uneven Progress in Advanced Breast Cancer Care
ABC Global Alliance's landmark Advanced Breast Cancer Global Decade Report 2015–2025 was recently released and published in The Breast. The report highlights significant advancements made over the past decade that have transformed care for patients with advanced breast cancer, but also reveals gaps ...
Model for Predicting Risk of Heart Failure or Cardiomyopathy After Breast Cancer Treatment
In a study reported in JAMA Oncology, Barac et al developed a risk prediction model for heart failure or cardiomyopathy (HF/CM) after breast cancer treatment.
Study Details
The aim of the study was to construct a model predicting the 10-year risk of developing HF/CM in women receiving systemic...
Study Finds Gaps Exist in Quality of Cancer Care for Incarcerated People
In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older.
As the incarcerated population ages, cancer has become one of the greatest threats to their health. And despite the growing prevalence, cancer...
Impact of Concomitant Noncancer Medications on Outcomes in Breast Cancer
An evaluation of noncancer medications used concomitantly with cancer therapies for patients with breast cancer showed that proton pump inhibitors specifically were associated with worse survival outcomes and with an increased risk of grade 3 or higher adverse events than other classes of therapy....
NCCN Guidelines to Be Integrated Into OpenEvidence's Medical AI Platform
The National Comprehensive Cancer Network (NCCN) has entered into a licensing agreement with OpenEvidence that would make the NCCN Clinical Practice Guidelines in Oncology accessible through OpenEvidence's AI–powered medical platform.
“This collaboration will help clinicians access trusted...
Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment
Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the Western hemisphere, accounting for between 25% and 35% of all leukemias in the United States. According to the American Cancer Society, nearly 24,000 new cases of CLL will be diagnosed in the United States this year,...
Hepatic Arterial Infusion Pump Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma
In a Dutch phase II trial (PUMP-2) reported in the Journal of Clinical Oncology, Franssen et al found that use of hepatic arterial infusion pump (HAIP) chemotherapy with floxuridine, with or without concomitant gemcitabine, plus cisplatin showed good activity and improved overall survival in...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses...
First-Line Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
In an interim analysis of a Chinese phase III trial (HARMONi-6) reported in The Lancet, Chen et al found that the combination of ivonescimab—a bispecific antibody targeting PD-1 and VEGF—plus chemotherapy prolonged progression-free survival vs tislelizumab—an anti–PD-1 monoclonal antibody—plus...
Extended ERSPC Analysis Demonstrates Long-Term Mortality Benefit of PSA Screening for Prostate Cancer
In an updated analysis published in The New England Journal of Medicine, Roobol et al reported long-term findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) on the survival benefit of prostate-specific antigen (PSA) screening. The study, which was initiated in 1993, ...
RCC: Lenvatinib/Everolimus Extends PFS After PD-1 Inhibition
The combination of lenvatinib and everolimus significantly improved progression-free survival compared with cabozantinib in patients with metastatic clear cell renal cell carcinoma (ccRCC) that has progressed on PD-1 immune checkpoint inhibitors, according to findings from the phase II LenCabo...
New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress
The American Lung Association has released its 2025 “State of Lung Cancer” report, which reveals great strides in efforts to end lung cancer—the leading cause of cancer-related deaths in the United States. This year, nearly 227,000 people in the United States will be diagnosed with lung cancer....
Extensive LA-Area Fires Altered Blood Proteins in Firefighters
Researchers have found that firefighters who battled the massive urban fires in the Los Angeles area in January 2025 developed physiologic changes that may increase their risk of diseases, including cancer.
The research, which was published by Furlong et al in the Journal of Occupational and...
Oropharyngeal Cancer in the United States: Recent Estimates and Future Trends
Based on the results of a cross-sectional epidemiologic analysis published in JAMA Network Open, the incidence of oropharyngeal cancer has increased among older individuals in the United States. According to Cao et al, those with localized disease appeared to be undertreated, indicating the need...
$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening
The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening ...
Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5
As reported in the Journal of Clinical Oncology by Neelapu et al, the 5-year follow-up of the phase II ZUMA-5 trial has shown sustained responses with axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Study Details
In the single-arm,...
Study Finds Breast Cancer Risk Varies Between Different Hormonal Contraceptives
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a new study from Uppsala University, in which researchers followed more than 2 million women and teenage girls in Sweden to identify how different hormonal contraceptives affect...
Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors
In a phase III trial (STELLAR-303) reported in The Lancet, Hecht et al found that the combination of the multitargeted tyrosine kinase inhibitor zanzalintinib and atezolizumab improved overall survival vs regorafenib in patients with previously treated relapsed or refractory metastatic colorectal...
Experts Outline Roadmap for Clinical Implementation of AI in Pediatric CNS Tumor Management
A subcommittee of the RAPNO (Response Assessment in Pediatric Neuro-Oncology) consortium that is focused on artificial intelligence (AI-RAPNO) has released guidance on the responsible implementation of AI in pediatric neuro-oncology in the form of a two-part policy review published in The Lancet...
Metastatic ER-Positive, HER2-Negative Breast Cancer: Novel Treatment Combination Improves Progression-Free Survival
Patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full...
